Table 4.

Summary data (by stage and combined current total) of partially completed Mel 63 trial

Stage	Total	Regimen	Toxicity	Immune response
	Accrual (n)		# of DLT/# treated	# of dRsp/# treated
1	2	A	0/2	0/2
1	2	B	0/2	1/2
1	2	C	0/2	0/2
1	2	D	1/2	2/2
2	1	A	0/1	0/1
2	5	B	1/5	1/5
2	4	C	0/4	4/4
2	12	D	0/12	10/12
1 + 2	3	A	0 (0%)	0 (0%)
1 + 2	7	B	1 (14%)	2 (29%)
1 + 2	6	C	0 (0%)	4 (67%)
1 + 2	14	D	1 (7%)	12 (86%)